Keybank National Association OH Acquires Shares of 4,963 Charles River Laboratories International, Inc. $CRL

Keybank National Association OH bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, Holdings Channel reports. The institutional investor bought 4,963 shares of the medical research company’s stock, valued at approximately $990,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. Massachusetts Financial Services Co. MA bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at approximately $176,478,000. Ameriprise Financial Inc. boosted its position in shares of Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after acquiring an additional 575,039 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after acquiring an additional 511,901 shares during the last quarter. Balyasny Asset Management L.P. boosted its position in shares of Charles River Laboratories International by 722.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after acquiring an additional 381,432 shares during the last quarter. Finally, LSV Asset Management boosted its position in shares of Charles River Laboratories International by 1,773.0% during the 3rd quarter. LSV Asset Management now owns 297,800 shares of the medical research company’s stock valued at $46,594,000 after acquiring an additional 281,900 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CRL has been the subject of a number of research reports. Mizuho lowered their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, April 8th. JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Monday, April 20th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.36.

Charles River Laboratories International Stock Up 0.1%

Shares of CRL opened at $165.92 on Monday. The company has a market cap of $8.19 billion, a PE ratio of -56.05, a P/E/G ratio of 2.01 and a beta of 1.44. The business has a fifty day moving average of $169.78 and a 200 day moving average of $183.17. Charles River Laboratories International, Inc. has a 52-week low of $113.89 and a 52-week high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.Charles River Laboratories International’s revenue was down .8% on a year-over-year basis. During the same period last year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.97 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.